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Edited by Jesus AvilaAbstract Bacterially expressed human a-synuclein (a-syn) has
been widely used in structural and functional studies. Here we
show that 20% of human a-syn expressed in Escherichia coli
is mistranslated and that a Cys residue is incorporated at posi-
tion 136 instead of a Tyr. Site-directed mutagenesis of codon
136 (TAC to TAT) resulted in the expression of a-syn lacking
Cys. Although wild-type (Y136-TAC and Y136-TAT) and mu-
tant (C136-TGC) a-syn had similar propensities to assemble into
ﬁlaments, the levels of dimeric a-syn were increased by misincor-
poration. To avoid potential artefacts, we recommend use of the
Y136-TAT construct for the expression of human a-syn.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Filamentous a-synuclein (a-syn) inclusions in nerve cells or
glial cells are the deﬁning neuropathological feature of a group
of neurodegenerative diseases which includes Parkinson’s
disease (PD), dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA) [1]. In these so-called ‘‘a-synucleinopa-
thies’’, a-syn is deposited in a hyperphosphorylated and par-
tially ubiquitinated form [2,3]. Missense mutations (A30P,
E46K and A53T) in the a-syn gene cause familial forms of
PD and DLB [4–6]. Furthermore, multiplications (duplication
and triplication) of a region on the long arm of chromosome 4
that encompasses the a-syn gene cause an inherited form of
PD-dementia [7], indicating that the simple overproduction
of wild-type a-syn is suﬃcient to cause disease.
Recombinant a-syn readily assembles into ﬁlaments that
share many of the morphological and biochemical characteris-
tics of the ﬁlaments present in human brain [8]. Mutations
E46K and A53T in a-syn have been found to accelerate the
rate of ﬁlament assembly [9,10]. Mutation A30P has been re-Abbreviations: a-syn, a-synuclein; PD, Parkinson’s disease; DLB, de-
mentia with Lewy bodies; MSA, multiple system atrophy; ThS, thio-
ﬂavin S; RP-HPLC, reverse phase high-performance liquid
chromatography; MALDI-TOF/MS, matrix-assisted laser desorption
ionization-time of ﬂight/mass spectrometry
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doi:10.1016/j.febslet.2006.02.032ported to increase the total aggregation of a-syn, but to slow
the rate of mature ﬁlament formation [10].
The precise chain of events leading from soluble, monomeric
to insoluble, ﬁlamentous a-syn is not known. Biophysical stud-
ies have suggested that dimerization of a-syn is a rate-limiting
step in aggregation [11]. Human a-syn does not contain any
Cys residues and hence, covalent aggregate formation caused
by oxidation is restricted to dityrosine cross-links [12].
Here we report the unexpected ﬁnding that bacterially ex-
pressed human a-syn contains a signiﬁcant amount of Cys.
Analysis of dimeric a-syn showed that 20% of the recombi-
nant protein was mistranslated, with Cys at position 136 in-
stead of Tyr. Mutagenesis of codon 136 from TAC to TAT
resulted in the expression of a-syn lacking Cys. The ability
of Y136C a-syn to assemble into ﬁlaments was not changed
signiﬁcantly. However, dimerization of the mutated protein
was signiﬁcantly enhanced.2. Experimental procedures
2.1. Expression and puriﬁcation of wild-type and mutant human
a-syn
Human a-syn cDNA in bacterial expression plasmid
pRK172 was used [13]. Codon 136 was changed from TAC
to TAT or TGC by site-directed mutagenesis (Stratagene)
(Fig. 1). All constructs were veriﬁed by DNA sequencing.
Wild-type and mutant proteins were expressed in Escherichia
coli BL21 (DE3) cells and puriﬁed using boiling, Q-Sepharose
ion exchange chromatography and ammonium sulfate precip-
itation. a-Syn proteins were dialyzed against 30 mM Tris–HCl,
pH 7.5, and cleared using a 20 min centrifugation at
113000 · g. Following separation by reverse phase high-per-
formance liquid chromatography (RP-HPLC, Aquapore
RP300 column), the absorbance at 215 nm was measured
and compared with that of a-syn of known concentration, to
give the concentration of the freshly puriﬁed protein.2.2. Analysis of monomeric and dimeric a-syn by mass
spectrometry
a-Syn (6 mg/ml) was incubated for 7 days at 37 C in 30 mM
Tris–HCl, pH 7.5, containing 0.02% sodium azide. Following a
20 min centrifugation at 113000 · g, the supernatant was frac-
tionated on a Superdex 200 gel ﬁltration column (10 · 300 mm,
Amersham Bioscience) in 10 mM Tris–HCl, pH 7.5, containingblished by Elsevier B.V. All rights reserved.
AB
Fig. 1. Amino acid sequence (A) and cDNA sequence (B) of human a-syn. The four Tyr residues at positions 39, 125, 133 and 136 are highlighted.
TAT codes for 39Y, 125Y and 133Y, whereas TAC encodes 136Y. During bacterial expression, a Cys residue is misincorporated at position 136 in a
substantial fraction of a-syn.
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or without 2-mercaptoethanol (2ME) and analyzed by matrix-
assisted laser desorption ionization-time of ﬂight/mass spec-
trometry (MALDI-TOF/MS) using a Voyager-DE Pro mass
spectrometer (PerSeptive Biosystems). Monomeric and dimeric
a-syn was digested with TPCK-trypsin (Worthington Biochem-
ical Company) for 18 h at 37 C at an enzyme to substrate ratio
of 1:20, separated by RP-HPLC on a Superspher Select B col-
umn (2.1 · 125 mm, Merck) and analyzed by mass spectrome-
try. The carboxy-terminal a-syn peptide was further digested
for 18 h at 37 C with V8 protease (Sigma) at an enzyme to sub-
strate ratio of 1:10, followed by RP-HPLC. The separated tryp-
tic-V8 peptide was then reduced for 1 h at 37 C with 0.5%
dithiothreitol (DTT) in 0.5 M Tris–HCl, pH 8.5, desalted using
ZipTipC18 and analyzed by MALDI-TOF/TOF mass spec-
trometry using an Ultraﬂex (Bruker Daltonik GmbH) in a
LIFT mode [14], with a-cyano hydroxyl cinnamic acid as a
matrix.
2.3. Reduction and S-carboxymethylation of a-syn
Recombinant Y136-TAC and Y136-TAT a-syn (100 lg) was
reduced for 1.5 h at room temperature with 1 mg DTT in 50 ll
of 0.5 M Tris–HCl, pH 8.5, containing 7 M guanidine hydro-
chloride. Iodoacetic acid (2.5 mg) was added, followed by a
30 min incubation in the dark. The reaction mixture was then
dialyzed against 30 mM Tris–HCl, pH 7.5, digested for 2 h at
37 C with TPCK-trypsin at an enzyme to substrate ratio of
1:20 and separated by RP-HPLC.2.4. Filament assembly of Cys-containing a-syn
Recombinant human a-syn (1 mg/ml) was incubated with
shaking (200 rpm) for 96 h at 37 C in 50 ll of 30 mM Tris–
HCl, pH 7.5, containing 0.02% sodium azide. For a quantitative
assessment of ﬁlament formation, the amounts of sarkosyl-
insoluble a-syn and the levels of thioﬂavin S (ThS) ﬂuorescence
were measured as described [15].3. Results
3.1. Identiﬁcation of Cys-containing a-syn
Recombinant a-syn was incubated for 7 days at 37 C, and
fractioned by gel ﬁltration chromatography. Two protein peaks
were observed, which corresponded to monomeric and dimeric
a-syn, respectively. Dimer formation was not observed in the
presence of 2ME (Fig. 2A). Analysis of the monomer fraction
(peak 1) by MALDI-TOF/MS gave one major signal corre-
sponding to a molecular mass of 14460 (identical to the calcu-
lated molecular mass of monomeric human a-syn) (Fig. 2B).
Analysis of the dimer fraction (peak 2) gave a signal of molec-
ular mass 28799 (identical to the calculated molecular mass of
dimeric a-syn minus 121) (Fig. 2C). To analyze this diﬀerence
further, we compared the peptide maps of the tryptic digests
of monomeric and dimeric a-syn. We found that the carboxy-
terminal region of a-syn was modiﬁed in the dimer (see supple-
mentary material). To identify the site of dimerization, the car-
boxy-terminal tryptic peptide was digested with V8 protease,
Fig. 2. Analysis of monomeric and dimeric a-syn. (A), Bacterially
expressed a-syn was incubated for 7 days at 37 C. Following
ultracentrifugation, the supernatant was fractionated by gel ﬁltration
chromatography and peak 1 (monomer) and peak 2 (dimer) were run
on SDS–PAGE in the absence and the presence of 2ME and visualized
with Coomassie brilliant blue (CBB). (B,C), MALDI-TOF mass
spectrometry analysis of peaks 1 and 2.
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MALDI-TOF/TOF mass spectrometry. The product ion spec-
tra derived from fragmentation of the charged ion atm/z 1011.4
resulted in a series of b and y sequence ions corresponding to
the peptide GYQDCEPEA (Fig. 3). This peptide is identical
to residues 132–140 of a-syn, with the exception of residue
136, which is Cys instead of Tyr. The diﬀerence between pre-Fig. 3. MALDI-TOF/TOF mass spectrometry analysis of the dimeric peptid
peptide (residues 103–140) was digested with V8 protease, puriﬁed by RP-H
spectrometry. The product ion spectra derived from fragmentation of the ch
which corresponded to the peptide GYQDCEPEA (residues 132–140 of a-sydicted and true mass of the dimer (121) could be accounted
for by the mass diﬀerence between Tyr (163) and Cys (103).
3.2. Mutagenesis of codon 136 (TAC to TAT) of a-syn prevents
the misincorporation of cysteine
Human a-syn contains four Tyr residues (at positions 39,
125, 133 and 136) (Fig. 1A). Tyr 136 is encoded by TAC,
whereas the other three are encoded by TAT (Fig. 1B). We
therefore mutated codon 136 from TAC to TAT, and found
that Y136-TAC, but not Y136-TAT a-syn dimerised in the ab-
sence of 2ME (Fig. 4A). MALDI-TOF/MS analysis gave a ma-
jor signal at 14460 and no signal corresponding to Cys-
containing a-syn. Carboxymethylation of a-syn with codons
TAC and TAT at position 136 was then used to identify the
presence of Cys (Fig. 4B and C). The peptide maps of a-syn
with codon TAC showed that carboxymethylation generated
an extra peak at 16.7 min (arrowed in Fig. 4B). MALDI-
TOF/MS and LC/MS analyses conﬁrmed that this peak corre-
sponded to the peptide with carboxymethylated Cys. The ratio
of the peak area of carboxymethylated (16.7 min) to non-car-
boxymethylated (16.9 min) peptide was 1:4–5, indicating that
20–25% of recombinant a-syn carried the Y136C substitution
(Fig. 4B). By contrast, when the peptide maps of a-syn with
codon TAT before and after carboxymethylation were com-
pared, no signiﬁcant diﬀerences were observed (Fig. 4C).
MALDI-TOF/MS and LC/MS analyses conﬁrmed the absence
of Cys and carboxymethylated Cys-containing peptides.
3.3. Filament formation of Y136-TAC, Y136-TAT and
C136-TGC a-syn
Puriﬁed Y136 (TAC or TAT) and C136 a-syn were incu-
bated for 96 h at 37 C with agitation. Aliquots were removed
daily and ﬁlament formation assessed by quantifying the level
of sarkosyl-insoluble a-syn. All three proteins showed a similare following digestion with V8 protease. The dimeric carboxy-terminal
PLC, reduced with DTT and analyzed by MALDI-TOF/TOF mass
arged ion at m/z 1011.4 resulted in a series of b and y sequence ions,
n, with a Y136C mutation).
0 10080604020
0
1000
2000
3000
4000
5000
Y136-TAT
Y136-TAC
C136-TGC
Fig. 5. Filament formation of Y136-TAC, Y136-TAT and C136-TGC
a-syn. Recombinant a-syn (70 lM) was incubated with shaking.
Filament formation was monitored by measuring the levels of
sarkosyl-insoluble a-syn. The results are expressed as means ± S.E.M.
(n = 3).
Fig. 4. Mutagenesis of codon Y136 of a-syn prevents the misincorpo-
ration of Cys. (A) a-Syn (Y136-TAC and Y136-TAT) was run on SDS–
PAGE in the absence () and the presence (+) of 2ME and stained with
CBB. (B,C), Wild-type a-syn (Y136-TAC and Y136-TAT) was carbo-
xymethylated, digested with trypsin and separated by RP-HPLC.
Separation proﬁles of the tryptic digests Y136-TAC (B) and Y136-TAT
(C) a-syn before and after carboxymethylation. Cys-containing peptide
was detected in Y136-TAC, but not Y136-TAT, a-syn following
carboxymethylation (arrow at 16.7 min). These results were conﬁrmed
by MALDI-TOF/MS and LC/MS/MS analysis (data not shown).
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were obtained when ﬁlament formation was measured by
ThS ﬂuorescence (not shown).4. Discussion
We report here that bacterial expression of human a-syn re-
sults in the misincorporation of Cys instead of Tyr at position
136 in 20–25% of the material. Cys-containing a-syn was
found to dimerize through disulﬁde bond formation. Tyr 136
is encoded by TAC, unlike the other three Tyr residues in hu-
man a-syn (at positions 39, 125 and 133), which are encoded
by TAT. Mutagenesis of codon 136 from TAC to TAT re-sulted in the expression of a-syn lacking Cys. These ﬁndings
are reminiscent of protein 0.3 of bacteriophage T7, for which
misincorporation of Cys instead of Tyr (one out of four Tyr
residues) was observed upon bacterial expression [16]. Like co-
don 136 of human a-syn, Tyr 15 of protein 0.3 is encoded by
TAC, which is followed by GAA in the sequence. This suggests
that the misincorporation of Cys in protein 0.3 and in a-syn
may have resulted from a combination of codon usage and se-
quence context. It remains to be seen whether the same is true
of other recombinantly expressed proteins.
Recombinant a-syn is widely used for studying the protein’s
normal function and its abnormal assembly into ﬁlaments.
Multimerization is believed to be an early step in the assembly
of a-syn. We compared the ability of a-syn with Y136, C136
and a mixture of Y136 and C136 to assemble into ﬁlaments
in vitro. All three protein preparations formed similar numbers
of ﬁlaments with similar kinetics, as assessed by the amounts of
sarkosyl-insoluble material and ThS ﬂuorescence. This indi-
cates that the presence of a Cys residue at position 136 does
not signiﬁcantly inﬂuence ﬁlament assembly of a-syn in vitro.
It agrees with a recent study, which concluded that inclusion
formation of a-syn was increased for mutations Y39C and
Y125C, but not for mutations Y133C and Y136C [17].
In conclusion, the present ﬁndings show that a substantial
proportion of bacterially expressed human a-syn carries a Tyr
to Cys change at position 136. Dimerization of a-syn was signif-
icantly increased by the Cys miscorporation. This unexpected
diﬃculty, which may well give rise to artefactual ﬁndings, can
be avoided by expressing recombinant a-syn from a construct,
where codon 136 has been mutated from TAC to TAT.
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Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.febslet.2006.02.032.
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